Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Manja Brose"'
Autor:
Vianney Tricou, Brandon Essink, John E Ervin, Mark Turner, Ian Escudero, Martina Rauscher, Manja Brose, Inge Lefevre, Astrid Borkowski, Derek Wallace
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 17, Iss 3, p e0011124 (2023)
BackgroundYellow fever (YF) vaccination is often mandatory for travelers to YF-endemic areas. The areas with risk of YF partially overlap with those of dengue, for which there is currently no recommended vaccine available for dengue-naïve individual
Externí odkaz:
https://doaj.org/article/c6f7122f93b84fdc87e18dd196662f44
Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
Autor:
Shibadas Biswal, Jorge Fernando Mendez Galvan, Mercedes Macias Parra, Juan-Francisco Galan-Herrera, Monica Belisa Carrascal Rodriguez, Esteban Patricio Rodriguez Bueno, Manja Brose, Martina Rauscher, Inge LeFevre, Derek Wallace, Astrid Borkowski
Publikováno v:
Revista Panamericana de Salud Pública, Vol 45, Iss 67, Pp 1-11 (2021)
Objective. To describe the immunogenicity and safety of a tetravalent dengue vaccine (TAK-003) in healthy adolescents living in Mexico City, an area considered non-endemic for dengue (NCT03341637). Methods. Participants aged 12–17 years were random
Externí odkaz:
https://doaj.org/article/3e634197f1df46e6bd0517825679a613
Autor:
Vianney Tricou, Susannah Eyre, Mahadev Ramjee, Paul Collini, Zenaida Mojares, Edde Loeliger, Sanja Mandaric, Martina Rauscher, Manja Brose, Inge Lefevre, Nicolas Folschweiller, Derek Wallace
Publikováno v:
Vaccine. 41:1398-1407
Autor:
Shibadas Biswal, Charissa Borja-Tabora, Luis Martinez Vargas, Hector Velásquez, Maria Theresa Alera, Victor Sierra, Edith Johana Rodriguez-Arenales, Delia Yu, V Pujitha Wickramasinghe, Edson Duarte Moreira, Asvini D Fernando, Dulanie Gunasekera, Pope Kosalaraksa, Felix Espinoza, Eduardo López-Medina, Lulu Bravo, Suely Tuboi, Yanee Hutagalung, Pedro Garbes, Ian Escudero, Martina Rauscher, Svetlana Bizjajeva, Inge LeFevre, Astrid Borkowski, Xavier Saez-Llorens, Derek Wallace, Alys Concepción, Ana Cecilia Villarreal, Asvini Fernando, Chukiat Sirivichayakul, Edith Johanna Rodriguez-Arenales, Humberto Reynales, Kleber Luz, Jose Jimeno, LakKumar Fernando, Luis Rivera, Onanong Manacharoen, Pio Lopez, V. Pujitha Wickramasinghe, Reynaldo Dietze, Rivaldo Venâncio da Cunha, Veerachai Watanaveeradej, Manja Brose, Kelley Moss, Seetha Meyer, Vianney Tricou
Publikováno v:
The Lancet. 395:1423-1433
A substantial unmet need remains for safe and effective vaccines against dengue virus disease, particularly for individuals who are dengue-naive and those younger than 9 years. We aimed to assess the efficacy, safety, and immunogenicity of a live att
Autor:
Shibadas, Biswal, Humberto, Reynales, Xavier, Saez-Llorens, Pio, Lopez, Charissa, Borja-Tabora, Pope, Kosalaraksa, Chukiat, Sirivichayakul, Veerachai, Watanaveeradej, Luis, Rivera, Felix, Espinoza, LakKumar, Fernando, Reynaldo, Dietze, Kleber, Luz, Rivaldo, Venâncio da Cunha, José, Jimeno, Eduardo, López-Medina, Astrid, Borkowski, Manja, Brose, Martina, Rauscher, Inge, LeFevre, Svetlana, Bizjajeva, Lulu, Bravo, Derek, Wallace, Zenaida, Mojares
Publikováno v:
New England Journal of Medicine. 381:2009-2019
Dengue, a mosquito-borne viral disease, was designated a World Health Organization top 10 threat to global health in 2019.We present primary efficacy data from part 1 of an ongoing phase 3 randomized trial of a tetravalent dengue vaccine candidate (T
Autor:
Rodrigo DeAntonio, Derek Wallace, Xavier Sáez-Llorens, Maria Vargas, Debbie Mendoza, Onix De Suman, Astrid Borkowski, Inge Lefevre, Martina Rauscher, Manja Brose, Ana Cecilia Villarreal, Suely Tuboi, Nathali Montenegro, Sonia Mazara, Delia Yu, Luis Rivera, Epiphany Dato, Vianney Tricou, José Jimeno
Publikováno v:
Lancet (London, England). 395(10234)
Summary Background An unmet clinical need remains for an effective tetravalent dengue vaccine suitable for all age groups, regardless of serostatus. We assessed the immunogenicity and safety of three different dose schedules of a tetravalent dengue v
Autor:
Derek Wallace, Manja Brose, Ana Cecilia Villarreal, Xavier Sáez-Llorens, Epiphany Dato, Suely Tuboi, Vianney Tricou, Sonia Mazara, José Jimeno, Maria Vargas, Delia Yu, Luis Rivera, Astrid Borkowski, Martina Rauscher
Publikováno v:
The Lancet Infectious Diseases. 18:162-170
Summary Background Development of vaccines that are effective against all four dengue virus serotypes (DENV-1–4) in all age groups is important. Here, we present 18-month interim data from an ongoing study undertaken to assess the immunogenicity an
Autor:
Derek Wallace, Junxiong Pang, Martina Rauscher, Manja Brose, Vianney Tricou, Helen M. L. Oh, Yanee Hutagalung, Limin Wijaya, Shirin Kalimuddin, Li Min Ling, Yee Sin Leo, Jenny G. Low, Astrid Borkowski, Tau Hong Lee
Publikováno v:
Vaccine. 38(6)
Background Early formulations of Takeda’s tetravalent dengue vaccine candidate (TAK-003) have demonstrated notably higher neutralizing antibody responses against serotype 2 than other serotypes. Here, we assessed the immunogenicity and tolerability
Autor:
Haiyuan Zhu, Udo-Michael Goehring, Peter M.A. Calverley, Nicola A. Hanania, Paul Rowe, Mark T. Dransfield, Manja Brose, Jill P. Karpel
Publikováno v:
Respiratory Medicine. 108:366-375
SummaryBackgroundThis post-hoc analysis examined the impact of roflumilast on chronic obstructive pulmonary disease (COPD) exacerbations and lung function in patients with COPD who received concomitant long-acting β2-agonists (LABA) with or without
Autor:
Jian Kang, Manja Brose, Fuxin Hui, Chunxue Bai, Jinghua Yang, Huiping Li, Udo-Michael Goehring, Ping Chen, Haoyan Wang, Xiangdong Zhou, Li Zhao, Jinping Zheng, Frank Richard, Nanshan Zhong
Publikováno v:
Chest. 145:44-52
Background Roflumilast is the only oral phosphodiesterase 4 inhibitor indicated for use in the treatment of COPD. Previous studies of roflumilast have predominantly involved European and North American populations. A large study was necessary to dete